Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 4
2001 3
2002 4
2003 4
2004 4
2005 3
2006 4
2007 2
2008 2
2010 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2).
Sami S, Willerson JT. Sami S, et al. Tex Heart Inst J. 2010;37(3):262-75. Tex Heart Inst J. 2010. PMID: 20548800 Free PMC article. Review.
In Part 1 of this review, we discussed how plaque rupture is the most common underlying cause of most cases of unstable angina/non-ST-segment-elevation myocardial infarction (UA/NSTEMI) and how early risk stratification is vital for the timely d …
In Part 1 of this review, we discussed how plaque rupture is the most common underlying cause of most cases of unstable angina/non- …
The role of low-molecular-weight heparins in the management of unstable angina and non-ST elevation myocardial infarction.
Alwi I. Alwi I. Acta Med Indones. 2008 Oct;40(4):228-32. Acta Med Indones. 2008. PMID: 19530369 Free article. Review.
Non-ST elevation myocardial infarction (NSTEMI) is a subset clinical manifestation of acute coronary syndrome (ACS), which is usually caused by disruption of vulnerable atherosclerotic plaque, followed by thrombosis resulting various degree of o …
Non-ST elevation myocardial infarction (NSTEMI) is a subset clinical manifestation of acute coronary synd …
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Montalescot G, Bal-dit-Sollier C, Chibedi D, Collet JP, Soulat T, Dalby M, Choussat R, Cohen A, Slama M, Steg PG, Dubois-Randé JL, Metzger JP, Tarragano F, Guermonprez JL, Drouet L; ARMADA Investigators. Montalescot G, et al. Am J Cardiol. 2003 Apr 15;91(8):925-30. doi: 10.1016/s0002-9149(03)00105-x. Am J Cardiol. 2003. PMID: 12686329 Clinical Trial.
The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over unfractionated heparin (UFH) in patients with unstable angina pectoris (UAP) or non-ST-segment elevation myocardial …
The low-molecular-weight heparins (LMWHs) enoxaparin and dalteparin have shown superior and equivalent efficacy, respectively, over u …
Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
Rubboli A, Ottani F, Capecchi A, Brancaleoni R, Galvani M, Swahn E. Rubboli A, et al. Cardiology. 2007;107(2):132-9. doi: 10.1159/000094659. Epub 2006 Jul 21. Cardiology. 2007. PMID: 16864962 Review.
BACKGROUND: Intravenous unfractionated heparin (UFH) is recommended in ST-elevation acute myocardial infarction (STEMI), following thrombolysis with fibrin-specific agents. Subcutaneous low-molecular-weight heparins (LMWH), previously proven effective …
BACKGROUND: Intravenous unfractionated heparin (UFH) is recommended in ST-elevation acute myocardial infarction …
Efficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction.
Rubboli A. Rubboli A. Curr Cardiol Rev. 2008 Feb;4(1):63-71. doi: 10.2174/157340308783565438. Curr Cardiol Rev. 2008. PMID: 19924279 Free PMC article.
A 48-hour course of intravenous unfractionated heparin (UFH) is the standard of treatment in conjunction with fibrin-specific thrombolysis in ST-elevation myocardial infarction (STEMI). In recent trials, the efficacy and safety of in-hospital administr …
A 48-hour course of intravenous unfractionated heparin (UFH) is the standard of treatment in conjunction with fibrin-specific thrombolysis i …
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
Mälarstig A, Lindahl B, Wallentin L, Siegbahn A. Mälarstig A, et al. Arterioscler Thromb Vasc Biol. 2006 Jul;26(7):1667-73. doi: 10.1161/01.ATV.0000222908.78873.36. Epub 2006 Apr 20. Arterioscler Thromb Vasc Biol. 2006. PMID: 16627810 Clinical Trial.
METHODS AND RESULTS: Samples were obtained on admission from 2359 patients with non-ST elevation ACS randomized to an early invasive versus a conservative and to placebo controlled long-term dalteparin treatment in the FRISC-II study. ...In the placebo …
METHODS AND RESULTS: Samples were obtained on admission from 2359 patients with non-ST elevation ACS randomized to an e …
The role of low-molecular-weight heparin in the management of acute coronary syndromes.
Cohen M. Cohen M. J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):55S-61S. doi: 10.1016/s0735-1097(02)02901-7. J Am Coll Cardiol. 2003. PMID: 12644342 Free article. Review.
Enoxaparin is the only LMWH compound to have demonstrated sustained clinical and economic benefits in comparison with UFH in the management of unstable angina/ non-ST-segment elevation myocardial infarction (NSTEMI). Also, LMWH appears to be a r …
Enoxaparin is the only LMWH compound to have demonstrated sustained clinical and economic benefits in comparison with UFH in the management …
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
Lindahl B, Lindbäck J, Jernberg T, Johnston N, Stridsberg M, Venge P, Wallentin L. Lindahl B, et al. J Am Coll Cardiol. 2005 Feb 15;45(4):533-41. doi: 10.1016/j.jacc.2004.10.057. J Am Coll Cardiol. 2005. PMID: 15708700 Free article. Clinical Trial.
OBJECTIVES: The aim of this research was to describe N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP) levels over time in non-ST-segment elevation acute coronary syndromes (NSTEACS), to elucidate factors associated with changes of NT-proBNP l …
OBJECTIVES: The aim of this research was to describe N-terminal part of the pro-B-type natriuretic peptide (NT-proBNP) levels over time in …
Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M. Cohen M. Drugs. 2002;62(12):1755-70. doi: 10.2165/00003495-200262120-00005. Drugs. 2002. PMID: 12149045 Review.
This article reviews the use of low molecular weight heparin (LMWH) and antiplatelet agents in the treatment of unstable angina and non-ST segment elevation myocardial infarction (NSTEMI), which together account for 1 million hospitalisations an …
This article reviews the use of low molecular weight heparin (LMWH) and antiplatelet agents in the treatment of unstable angina and non …
28 results